498 related articles for article (PubMed ID: 20874042)
1. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.
Gabardi S; Baroletti SA
Pharmacotherapy; 2010 Oct; 30(10):1044-56. PubMed ID: 20874042
[TBL] [Abstract][Full Text] [Related]
2. Everolimus in clinical practice in long-term liver transplantation: an observational study.
Casanovas T; Argudo A; Peña-Cala MC
Transplant Proc; 2011; 43(6):2216-9. PubMed ID: 21839237
[TBL] [Abstract][Full Text] [Related]
3. Everolimus in clinical practice--renal transplantation.
Pascual J
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
[TBL] [Abstract][Full Text] [Related]
4. Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years.
Sola E; Lopez V; Gutierrez C; Cabello M; Burgos D; Molina MG; Hernandez D
Transplant Proc; 2010 Oct; 42(8):2859-60. PubMed ID: 20970551
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M
Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
[TBL] [Abstract][Full Text] [Related]
6. Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma.
Grgic T; Mis L; Hammond JM
Ann Pharmacother; 2011 Jan; 45(1):78-83. PubMed ID: 21177421
[TBL] [Abstract][Full Text] [Related]
7. Everolimus for stent-based intracoronary applications.
Grube E; Buellesfeld L
Rev Cardiovasc Med; 2004; 5 Suppl 2():S3-8. PubMed ID: 15184828
[TBL] [Abstract][Full Text] [Related]
8. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
[TBL] [Abstract][Full Text] [Related]
9. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
Grube E; Buellesfeld L
Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
[TBL] [Abstract][Full Text] [Related]
10. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation.
Zuckermann A; Manito N; Epailly E; Fiane A; Bara C; Delgado JF; Lehmkuhl H; Ross H; Eisen H; Chapman J; Valantine H
J Heart Lung Transplant; 2008 Feb; 27(2):141-9. PubMed ID: 18267219
[TBL] [Abstract][Full Text] [Related]
11. Clinical evidence on the use of anti-mTOR drugs in renal transplantation.
Hernández D; Martínez D; Gutiérrez E; López V; Gutiérrez C; García P; Cobelo C; Cabello M; Burgos D; Sola E; González-Molina M
Nefrologia; 2011; 31(1):27-34. PubMed ID: 21270910
[TBL] [Abstract][Full Text] [Related]
12. A drug safety evaluation of everolimus in kidney transplantation.
Holdaas H; Midtvedt K; Åsberg A
Expert Opin Drug Saf; 2012 Nov; 11(6):1013-22. PubMed ID: 22954349
[TBL] [Abstract][Full Text] [Related]
13. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.
Mártinez JM; Pulido LB; Bellido CB; Usero DD; Aguilar LT; Moreno JL; Artacho GS; Díez-Canedo JS; Gómez LM; Bravo MA
Transplant Proc; 2010 Mar; 42(2):641-3. PubMed ID: 20304212
[TBL] [Abstract][Full Text] [Related]
14. Clinical recommendations for the use of everolimus in heart transplantation.
Manito N; Delgado JF; Crespo-Leiro MG; González-Vílchez F; Almenar L; Arizón JM; Díaz B; Fernández-Yáñez J; Mirabet S; Palomo J; Rodríguez Lambert JL; Roig E; Segovia J
Transplant Rev (Orlando); 2010 Jul; 24(3):129-42. PubMed ID: 20619801
[TBL] [Abstract][Full Text] [Related]
15. Conversion to everolimus in maintenance patients--current clinical strategies.
Pohanka E
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii24-9. PubMed ID: 16815853
[TBL] [Abstract][Full Text] [Related]
16. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Valantine H
J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin.
Lehmkuhl H; Hetzer R
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S201-5; discussion S210-1. PubMed ID: 15774323
[TBL] [Abstract][Full Text] [Related]
18. Everolimus: efficacy and safety in cardiac transplantation.
Schaffer SA; Ross HJ
Expert Opin Drug Saf; 2010 Sep; 9(5):843-54. PubMed ID: 20701555
[TBL] [Abstract][Full Text] [Related]
19. Everolimus: a guide to its use in liver transplantation.
Keating GM; Lyseng-Williamson KA
BioDrugs; 2013 Aug; 27(4):407-11. PubMed ID: 23696253
[TBL] [Abstract][Full Text] [Related]
20. Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients.
Budde K; Neumayer HH; Lehne G; Winkler M; Hauser IA; Lison A; Fritsche L; Soulillou JP; Fauchald P; Dantal J;
Nephrol Dial Transplant; 2004 Oct; 19(10):2606-14. PubMed ID: 15316094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]